Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare CHOP versus CEOP-induced cardiotoxicity in patients with
aggressive B-cell lymphoma. The hypothesis is epirubicin is associated with less
cardiotoxicity without compromising the efficacy.